Premium
Olanzapine‐fluoxetine combination has some benefit, but placebo effect and adverse events high
Publication year - 2015
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30031
Subject(s) - olanzapine , quetiapine , fluoxetine , mania , psychiatry , adverse effect , bipolar disorder , medicine , placebo , treatment of bipolar disorder , risperidone , psychology , lithium (medication) , pharmacology , schizophrenia (object oriented programming) , alternative medicine , receptor , pathology , serotonin
Adolescents and children diagnosed with bipolar disorder (BP) have a significantly reduced quality of life, including greater risk of suicidal behavior. Rapid intervention is critical, but unfortunately pharmacological treatments are challenging, with antidepressants sometimes causing manic symptoms. While there are medications effective in treating mania, the depressive phase is more difficult to treat. Only three medications are approved by the Food and Drug Administration (FDA) for the acute treatment of bipolar depression in adults: quetiapine, lurasidone, and olanzapine/fluoxetine combination (OFC).